We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Metered Nicotine Inhaler Doubles Smoking Cessation

By HospiMedica International staff writers
Posted on 25 May 2016
A new study shows that smokers who used an active nicotine pressurized metered dose inhaler (pMDI) were twice as likely to quit smoking as those using a placebo inhaler.

Researchers at the University of Otago (Wellington, New Zealand) conducted a double blind, randomized, placebo-controlled trial involving 502 adults who smoked at least nine cigarettes per day, and who wanted to quit. The patients were randomized to pMDI and active nicotine patch, versus placebo pMDI and active nicotine patch. The aerosols were used for six months and the patches daily for four months. The primary outcome was prolonged smoking cessation for seven consecutive days.

Image: A pressurized metered nicotine dose inhaler (Photo courtesy of the University of Otago).
Image: A pressurized metered nicotine dose inhaler (Photo courtesy of the University of Otago).

The results showed that 31.71% subjects in the active group were smoke abstinent, compared to only 17.97% in the control group. Participants in the active nicotine aerosol group reported mild coughing, which decreased with regular use. The researchers concluded that the pMDI nicotine inhaler, similar to that used for treating asthma, could offer an alternative therapeutic option for smoking cessation. The study was published on May 17, 2016 in Nicotine & Tobacco Research.

“Currently most smokers use nicotine patches to help them stop smoking. This study shows that if you add a nicotine inhaler to a nicotine patch, it doubles the chances of quitting over a nicotine patch alone,” said senior author Professor Julian Crane, MD. “New Zealand has been a world leader in tobacco control public policy and this new home-grown development offers a world-first opportunity to help the 80% or more of smokers who want to quit achieve their aims.”

Nicotine is an alkaloid found in the nightshade plant family that constitutes approximately 0.6–3% of the dry weight of tobacco, with biosynthesis taking place in the roots and accumulation occurring in the leaves. In low concentrations (an average cigarette yields about 1 mg of absorbed nicotine), the substance acts as a stimulant in mammals and is the main factor responsible for the dependence-forming properties of tobacco smoking.

Related Links:
University of Otago



Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Silver Member
Compact 14-Day Uninterrupted Holter ECG
NR-314P
New
Illuminator
Trimline Basic

Latest Critical Care News

First-Of-Its-Kind Dissolvable Stent to Improve Outcomes for Patients with Severe PAD

AI Brain-Age Estimation Technology Uses EEG Scans to Screen for Degenerative Diseases

Wheeze-Counting Wearable Device Monitors Patient's Breathing In Real Time